Issues
-
Cover Image
Cover Image
Current modalities for predicting prostate cancer outcome are largely based on clinical features of tumors, whereas molecular markers that distinguish indolent versus aggressive tumors are lacking. Using an integrative approach that combines gene expression profiling of a mouse model with expression validation using human prostate cancer tissue microarrays, we find that the AP-1 transcription factors c-Fos and c-Jun are markers of advanced prostate cancer and in particular that c-Jun is associated with disease recurrence. Our findings provide a striking example of how accurate mouse models can inform on molecular processes involved in the progression and recurrence of human cancer. For details, see the article by Ouyang and colleagues on page 2132 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Priority Reports
Molecular Biology, Pathobiology, and Genetics
Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer
Origins and Prevalence of the American Founder Mutation of MSH2
Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study
Cell, Tumor, and Stem Cell Biology
Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-α Expression in Breast Cancer Cells
c-Jun NH2-Terminal Kinase Activating Kinase 1/Mitogen-Activated Protein Kinase Kinase 4–Mediated Inhibition of SKOV3ip.1 Ovarian Cancer Metastasis Involves Growth Arrest and p21 Up-regulation
Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer
Tumor Microenvironment
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors
Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Immunology
Conjugation of Human Topoisomerase 2α with Small Ubiquitin-like Modifiers 2/3 in Response to Topoisomerase Inhibitors: Cell Cycle Stage and Chromosome Domain Specificity
A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
Endocrinology
Insulin-like Growth Factor-I–Dependent Up-regulation of ZEB1 Drives Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells
Clinical Research
Epidemiology
Prevention
Tribute
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.